CY1120635T1 - Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης - Google Patents

Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης

Info

Publication number
CY1120635T1
CY1120635T1 CY181100839T CY181100839T CY1120635T1 CY 1120635 T1 CY1120635 T1 CY 1120635T1 CY 181100839 T CY181100839 T CY 181100839T CY 181100839 T CY181100839 T CY 181100839T CY 1120635 T1 CY1120635 T1 CY 1120635T1
Authority
CY
Cyprus
Prior art keywords
aminoeteralyl
benzamids
kinase inhibitors
compounds
present
Prior art date
Application number
CY181100839T
Other languages
English (en)
Inventor
Jeffrey T Bagdanoff
Yu Ding
Wooseok Han
Zilin Huang
Qun Jiang
Xiang Kou
Patrick Lee
Mika Lindvall
Zhongcheng Min
Yue Pan
Sabina Pecchi
Keith Bruce Pfister
Daniel Poon
Vivek Rauniyar
Xiaojing Michael Wang
Qiong Zhang
Jianguang Zhou
Shejin Zhu
Jeff Xianming Jin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1120635T1 publication Critical patent/CY1120635T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει μια ένωση του τύπου (I) ή ένα άλας αυτής και θεραπευτικές χρήσεις αυτών των ενώσεων. Η παρούσα εφεύρεση παρέχει περαιτέρω φαρμακευτικές συνθέσεις που περιέχουν αυτές τις ενώσεις, και συνθέσεις που περιέχουν αυτές τις ενώσεις με έναν θεραπευτικό συν- παράγοντα.
CY181100839T 2013-11-01 2018-08-10 Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης CY1120635T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361898761P 2013-11-01 2013-11-01
CN2014088409 2014-10-11
PCT/US2014/062913 WO2015066188A1 (en) 2013-11-01 2014-10-29 Aminoheteroaryl benzamides as kinase inhibitors

Publications (1)

Publication Number Publication Date
CY1120635T1 true CY1120635T1 (el) 2019-12-11

Family

ID=51932581

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181100839T CY1120635T1 (el) 2013-11-01 2018-08-10 Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης

Country Status (36)

Country Link
US (4) US9242996B2 (el)
EP (1) EP3063143B1 (el)
JP (2) JP6219507B2 (el)
KR (1) KR101910720B1 (el)
CN (1) CN105658646B (el)
AP (1) AP2016009099A0 (el)
AU (1) AU2014342338B2 (el)
BR (1) BR112016008133B1 (el)
CA (1) CA2922532C (el)
CL (1) CL2016000807A1 (el)
CU (1) CU24425B1 (el)
CY (1) CY1120635T1 (el)
DK (1) DK3063143T3 (el)
DO (1) DOP2016000085A (el)
EA (1) EA032754B1 (el)
ES (1) ES2684360T3 (el)
HR (1) HRP20181287T1 (el)
HU (1) HUE039306T2 (el)
IL (1) IL244240B (el)
JO (1) JO3452B1 (el)
LT (1) LT3063143T (el)
MX (1) MX355480B (el)
PE (1) PE20161073A1 (el)
PH (1) PH12016500467B1 (el)
PL (1) PL3063143T3 (el)
PT (1) PT3063143T (el)
RS (1) RS57641B1 (el)
SG (1) SG11201601467SA (el)
SI (1) SI3063143T1 (el)
SV (1) SV2016005180A (el)
TN (1) TN2016000081A1 (el)
TR (1) TR201811764T4 (el)
TW (1) TWI663153B (el)
UY (1) UY35813A (el)
WO (1) WO2015066188A1 (el)
ZA (1) ZA201601102B (el)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9242996B2 (en) 2013-11-01 2016-01-26 Novartis Ag Aminoheteroaryl benzamides as kinase inhibitors
US10642873B2 (en) * 2014-09-19 2020-05-05 Microsoft Technology Licensing, Llc Dynamic natural language conversation
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP4245376A3 (en) 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
US10449211B2 (en) 2015-03-10 2019-10-22 Aduro Biotech, Inc. Compositions and methods for activating “stimulator of interferon gene”—dependent signalling
EP4378957A3 (en) 2015-07-29 2024-08-07 Novartis AG Combination therapies comprising antibody molecules to pd-1
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
CN106198778B (zh) * 2016-06-24 2018-11-20 南京优科制药有限公司 一种同时测定吉非替尼及其有关物质的方法
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
CN109715163B (zh) * 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
CN108456213B (zh) * 2017-02-22 2021-01-15 浙江九洲药业股份有限公司 一种3-氟-4-羟基环己烷羧酸酯的制备方法
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
IL311471A (en) 2017-05-02 2024-05-01 Novartis Ag Combined treatment
MX2019014861A (es) 2017-06-30 2020-02-13 Bristol Myers Squibb Co Compuestos de quinolinilciclohexilpropanamida sustituidos y metodos mejorados para su preparacion.
CN109467538A (zh) * 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
EP3694518A1 (en) * 2017-10-12 2020-08-19 Novartis AG Combinations of mdm2 inhibitors with inhibitors of erk for treating cancers
CA3085460A1 (en) * 2017-12-22 2019-06-27 Petra Pharma Corporation Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors
TW201940165A (zh) 2018-01-29 2019-10-16 美商卡普勒斯療法有限責任公司 包含6員中心環的srebp抑制劑
IL277071B2 (en) 2018-03-08 2024-07-01 Incyte Corp Aminopyrizine diol compounds as PI3K–y inhibitors
CA3094780A1 (en) * 2018-03-30 2019-10-03 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, trametinib and an erk inhibitor
CN108727354A (zh) * 2018-05-16 2018-11-02 张玉叶 一种甲酰胺类衍生物及其在抗肿瘤药物中的应用
CN108727355A (zh) * 2018-05-16 2018-11-02 张玉叶 一种甲酰胺类衍生物、制备方法及其在抗肿瘤药物中的应用
CN108558844A (zh) * 2018-05-16 2018-09-21 张玉叶 一种甲酰胺类衍生物及其在抗肿瘤药物中的应用
CN108440514A (zh) * 2018-05-16 2018-08-24 张玉叶 一种甲酰胺类衍生物、制备方法及其在抗肿瘤药物中的应用
CN108440513A (zh) * 2018-05-16 2018-08-24 张玉叶 一种甲酰胺类衍生物及其在抗肿瘤药物中的应用
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
JP7422732B2 (ja) * 2018-07-18 2024-01-26 アストラゼネカ・アクチエボラーグ Ｊａｋ阻害化合物のキシナホ酸塩
CN110275010B (zh) * 2019-06-21 2022-07-01 中山大学孙逸仙纪念医院 一种用于治疗前列腺癌药物的P38a MAPK信号通路抑制剂的筛选方法
CN114025758A (zh) * 2019-07-01 2022-02-08 钱立刚 P2x7r拮抗剂
WO2021026672A1 (en) 2019-08-09 2021-02-18 Novartis Ag Heterocyclic wdr5 inhibitors as anti-cancer compounds
WO2021165849A1 (en) 2020-02-18 2021-08-26 Novartis Ag Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc
JP2023516155A (ja) 2020-02-28 2023-04-18 ノバルティス アーゲー ダブラフェニブ、ｅｒｋ阻害剤及びｒａｆ阻害剤又はｐｄ－１阻害剤を含む三重の医薬品の組合せ
WO2021171261A1 (en) 2020-02-28 2021-09-02 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor
EP4149472A1 (en) 2020-05-12 2023-03-22 Novartis AG Therapeutic combinations comprising a craf inhibitor
WO2022074600A1 (en) 2020-10-08 2022-04-14 Novartis Ag Use of an erk inhibitor for the treatment of myelofibrosis
EP4225316A1 (en) 2020-10-08 2023-08-16 Novartis AG Use of an erk inhibitor for the treatment of myelofibrosis
IL304891A (en) 2021-02-02 2023-10-01 Servier Lab Selective Protech BCL-XL compounds and methods of use
KR20240035390A (ko) 2021-05-11 2024-03-15 오릭 파마슈티칼스, 인크. 폴로 유사 키나제 4 억제제
WO2022259157A1 (en) 2021-06-09 2022-12-15 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor
WO2023225320A1 (en) 2022-05-20 2023-11-23 Novartis Ag Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2023225336A1 (en) 2022-05-20 2023-11-23 Novartis Ag Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2023245015A2 (en) * 2022-06-14 2023-12-21 Schrödinger, Inc. Phenyl amide compounds and methods of use
WO2024104441A1 (en) * 2022-11-17 2024-05-23 Insilico Medicine Ip Limited Salt-inducible kinases (sik) inhibitors and methods of uses thereof
WO2024189481A1 (en) 2023-03-10 2024-09-19 Novartis Ag Panras inhibitor antibody-drug conjugates and methods of use thereof
WO2024213656A1 (en) 2023-04-13 2024-10-17 Syngenta Crop Protection Ag Imidazo[1,2-a]pyrazine derivatives
CN116444496B (zh) * 2023-06-16 2023-11-24 药康众拓(北京)医药科技有限公司 一种嘧啶联氘代吡唑类化合物及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1863780A (zh) * 2002-08-14 2006-11-15 沃泰克斯药物股份有限公司 蛋白激酶抑制剂及其应用
WO2004016597A2 (en) 2002-08-14 2004-02-26 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2006083477A2 (en) * 2005-01-07 2006-08-10 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
AU2006326616B2 (en) 2005-12-13 2012-09-06 Merck Sharp & Dohme Llc Polycyclic indazole derivatives that are ERK inhibitors
GB0625659D0 (en) * 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP2155722B1 (en) 2007-06-05 2013-08-14 Merck Sharp & Dohme Corp. Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer
UY33469A (es) * 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
ES2639426T3 (es) * 2011-03-04 2017-10-26 Lexicon Pharmaceuticals, Inc. Inhibidores de cinasa MST1 y métodos para su uso
LT2820009T (lt) 2012-03-01 2018-05-10 Array Biopharma, Inc. Serino (treonino) kinazės inhibitoriai
WO2015051043A1 (en) 2013-10-01 2015-04-09 Amgen Inc. Biaryl acyl-sulfonamide compounds as sodium channel inhibitors
US9242996B2 (en) * 2013-11-01 2016-01-26 Novartis Ag Aminoheteroaryl benzamides as kinase inhibitors

Also Published As

Publication number Publication date
CL2016000807A1 (es) 2016-07-08
MX355480B (es) 2018-04-19
UY35813A (es) 2015-05-29
KR101910720B1 (ko) 2018-10-22
WO2015066188A1 (en) 2015-05-07
MX2016004938A (es) 2016-07-11
EA032754B1 (ru) 2019-07-31
US20190247392A1 (en) 2019-08-15
SI3063143T1 (sl) 2018-09-28
IL244240B (en) 2018-01-31
EP3063143B1 (en) 2018-05-16
US20180028532A1 (en) 2018-02-01
PH12016500467A1 (en) 2016-05-16
US10660888B2 (en) 2020-05-26
SG11201601467SA (en) 2016-05-30
SV2016005180A (es) 2016-11-21
US20150126490A1 (en) 2015-05-07
AP2016009099A0 (en) 2016-03-31
ES2684360T3 (es) 2018-10-02
DK3063143T3 (en) 2018-08-20
JO3452B1 (ar) 2020-07-05
PH12016500467B1 (en) 2016-05-16
CA2922532A1 (en) 2015-05-07
US10188649B2 (en) 2019-01-29
ZA201601102B (en) 2017-09-27
AU2014342338A1 (en) 2016-03-10
HRP20181287T1 (hr) 2018-10-05
US9763937B2 (en) 2017-09-19
PE20161073A1 (es) 2016-10-30
CU20160052A7 (es) 2017-02-02
HUE039306T2 (hu) 2018-12-28
JP2018076287A (ja) 2018-05-17
CA2922532C (en) 2023-09-19
PL3063143T3 (pl) 2018-10-31
US20170182038A1 (en) 2017-06-29
US9242996B2 (en) 2016-01-26
EA201690598A1 (ru) 2016-10-31
EP3063143A1 (en) 2016-09-07
CN105658646B (zh) 2018-11-27
CN105658646A (zh) 2016-06-08
TW201607926A (zh) 2016-03-01
JP6388991B2 (ja) 2018-09-12
RS57641B1 (sr) 2018-11-30
BR112016008133B1 (pt) 2020-11-24
JP2016540728A (ja) 2016-12-28
LT3063143T (lt) 2018-08-10
PT3063143T (pt) 2018-10-19
NZ717223A (en) 2021-05-28
TN2016000081A1 (en) 2017-07-05
TR201811764T4 (tr) 2018-09-21
CU24425B1 (es) 2019-06-04
AU2014342338B2 (en) 2016-12-01
TWI663153B (zh) 2019-06-21
JP6219507B2 (ja) 2017-10-25
DOP2016000085A (es) 2016-06-15
IL244240A0 (en) 2016-04-21
KR20160078957A (ko) 2016-07-05

Similar Documents

Publication Publication Date Title
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
CY1120703T1 (el) Ετεροκυκλικες ενωσεις και χρησεις αυτων
CY1119707T1 (el) Ενωσεις διαρυλικου αμιδιου ως αναστολεις της κινασης
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
PH12017500416A1 (en) Compounds and compositions as raf kinase inhibitors
CR20160099A (es) Formulación de inhibidores de la syk
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
CY1122313T1 (el) Ορβεπιταντη για την αγωγη του χρονιου κνησμου
RS54730B1 (sr) Inhibitori beta sekretaze
EA201690764A1 (ru) Ингибитор грелин-o-ацилтрансферазы
EA201690911A1 (ru) Соединения диметилбензойной кислоты
EA201590552A1 (ru) Аминохинолины в качестве ингибиторов киназы
EA201592268A1 (ru) Дигидропиридиноновые ингибиторы mgat2
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
CR20150417A (es) Compuestos de azetidiniloxifenilpirrolidina
UA113086C2 (xx) Піразольні сполуки як інгібітори sglt1
CY1121116T1 (el) Νεα μεθοδος για την συνθεση αγομελατινης
EA201600323A1 (ru) Производные пиперазина и их применение в качестве лекарственного средства
EA201990313A1 (ru) Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека
CY1119540T1 (el) Υποκατασταθεντα απο γλυκοπυρανοσυλιο παραγωγα ινδολο-ουριας και η χρηση τους ως αναστολεις sglt